Avita MedicalRCEL
About: Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Employees: 260
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
123% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 13
109% more call options, than puts
Call options by funds: $557K | Put options by funds: $266K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
26% more capital invested
Capital invested by funds: $65.3M [Q3] → $82.4M (+$17.1M) [Q4]
9% more funds holding
Funds holding: 67 [Q3] → 73 (+6) [Q4]
1.11% more ownership
Funds ownership: 23.45% [Q3] → 24.57% (+1.11%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
D. Boral Capital Jason Kolbert 22% 1-year accuracy 81 / 364 met price target | 126%upside $22 | Buy Maintained | 10 Apr 2025 |
Financial journalist opinion
Based on 3 articles about RCEL published over the past 30 days
